This website is intended for healthcare professionals only.

Hospital Healthcare Europe
Hospital Pharmacy Europe     Newsletter          

Press Releases

Take a look at a selection of our recent media coverage:

First-in-class oral interleukin-23 inhibitor found to be effective for psoriasis

17th July 2023

JNJ-77242113 is the first oral peptide able to directly bind to the interleukin-23 (IL-23) receptor, and appears to be effective in moderate to severe plaque psoriasis.

Data presented at the recent 25th World Congress of Dermatology (WCD) from the FRONTIER 1 trial, suggests that JNJ-77242113 (also known as JNJ-2113), a first-in-class oral IL-23 inhibitor, provides a significant improvement in Psoriasis Area Severity Index (PASI) scores compared to a placebo in a dose ranging study.

In the phase 2, randomised, placebo-controlled trial presented at WCD, patients with moderate-to-severe plaque psoriasis were randomised to six different dosing regimens taken either daily (QD) or twice a day (BID) for a total of 16 weeks: 25 mg QD, 50 mg QD, 100 mg QD, or 25 mg BID, 100 mg BID, 100 mg BID or placebo.

The primary outcome was the proportion of patients achieving a 75% improvement in PASI scores at week 16 – known as PASI75. In addition, the team also considered the proportion achieving a PASI90.

JNJ-77242113 and psoriasis outcomes

At week 16, only 9.3% of participants achieved a PASI75. In contrast, a PASI75 was achieved by 37.2% of those given 25 mg and 58.1% of those with a 50 mg daily dose. The highest proportion of patients achieving a PASI75 was for the 100 mg twice daily dose (78.6%).

In addition, while only 2.3% of placebo patients achieved a PASI90, this occurred with 25.6% of those given the 25 mg dose and 59.5% of those given 100 mg twice daily.

For both PASI75 and PASI90 all comparisons with placebo were statistically significant (nominal p < 0.02).

The proportions of patients with adverse events were similar for the different doses of JNJ-77242113 and the placebo group, mainly Covid-19 and nasopharyngitis with no dose-dependent trends.

A recent study found that use of biologics in women with psoriasis who are either pregnant or planning to conceive is not associated with an increased risk of miscarriage, abortion or congenital malformations.

Risankizumab not beneficial in patients with severe asthma

4th November 2021

Risankizumab use in patients with severe asthma is of no benefit and was found to shorten the time to asthma worsening compared with placebo.

Use of risankizumab in patients with severe asthma led to a reduction in the time to worsening compared to placebo. This was the finding of a randomised trial of the drug by a team from the Institute for Lung Health, Department of Respiratory Sciences, University of Leicester, Leicester, UK. Asthma is due to inflammation and a narrowing of the airways and this leads to the major symptoms of cough, wheeze, chest tightness and a shortness of breath. In 2019, asthma was estimated to affect 262 million people and caused 461000 deaths. The prevalence of severe asthma has been estimated from a Dutch study to be 3.6% or 10.4 patients per 10,000.

The cytokine, interleukin-23 (IL-23) produced by T-helper 17 cells, has been implicated in the development of allergic asthma and in fact, serum IL-23 levels have been found to elevated in asthmatic children and therefore could be used as a marker of bronchial function impairment. Risankizumab binds to and inhibits IL-23 and this action has proved to be of value in psoriasis and Crohn’s disease and could therefore benefit patients with severe asthma although there is a lack of data in support of this view.

For the present study, the Leicester researchers conducted a phase 2a, randomised, double-blind trial to assess the efficacy and safety of risankizumab in adults with severe, persistent asthma. Patients aged 18 to 75 years and who were currently using medium to high-dose inhaled glucocorticoids with at least one additional controller medications and had a history of one or two severe asthma exacerbations in the previous 12 months, were included in the study. Individuals were randomised 1:1 to receive either 90 mg risankizumab or placebo, subcutaneously, once every 4 weeks for a total of 24 weeks. The primary endpoint was the time to the first asthma worsening, which was defined in several different ways, including a deterioration from baseline on 2 or more consecutive days or an 50% increase in the number of rescue medication puffs in a 24 hour period.


A total of 213 patients were analysed, 105 with a mean age of 54 years (65.7% female) given risankizumab. The median time to the first asthma worsening was 40 days in the risankizumab group and 86 days in the placebo arm (hazard ratio, HR = 1.46, 95% CI 1.05 – 2.04, p = 0.03). In addition, the hazard ratio for the time to the first severe exacerbation was 1.18 (95% CI 0.76 – 1.83) and hence not significantly different to placebo.

The researchers also examined sputum gene expression and found that in patients using risankizumab, there was down-regulation of genes associated with IL-23 at the end of the treatment period but this effect was absent at week 20, suggesting that attenuation of IL-23 signally was not consistent throughout the study.

The authors concluded that risankizumab was not beneficial for severe asthma and that it was actually worse than placebo. The suggested that their data challenged the view that targeting IL-23 was of value in the treatment of asthma.


Brightling CE et al. Risankizumab in Severe Asthma — A Phase 2a, Placebo-Controlled Trial. New Eng J Med 2021